<unk>  sold under the brand name Ryplazim, is a biologic medication for the treatment of hypoplasminogenemia<unk> deficiency type 1). It is purified from human plasma and is administered intravenously. The most common side effects include abdominal pain, bloating, nausea, bleeding, limb pain, fatigue, constipation, dry mouth, headache, dizziness, joint pain, and back pain. Individuals with hypoplasminogenemia lack a protein called<unk>  which is responsible for the ability of the body to break down fibrin clots.<unk> deficiency leads to an accumulation of fibrin, causing the development of growths (lesions) that can impair normal tissue and organ function and may lead to blindness when these lesions affect the eyes.<unk>  human-tvmh was approved for medical use in the United States in June 2021. It is the first therapy for hypoplasminogenemia approved by the U.S. Food and Drug Administration (FDA).
Plasminogen 
Thrombin
Fibrinogen
Platelet-activating factor
Hemostat
Prothrombinase
Serpin
Platelet-rich fibrin